Novo Nordisk: CHMP recommends EU approval for Wegovy 7.2 mg single-dose pen

Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for Wegovy® 7.2 mg (once-weekly injectable semaglutide 7.2 mg) in a single-dose pen for people living with obesity in the EU. The company anticipates launching the product in the EU in Q3 2026. Clinical trials showed Wegovy® 7.2 mg achieved an average weight loss of 20.7% in participants with obesity, with approximately one in three patients achieving 25% or greater weight loss. The single-dose pen is already approved and available in the US (as Wegovy® HD) and UK.